Gamma Secretase - Pipeline Review, H2 2020
Gamma Secretase - Pipeline Review, H2 2020
SUMMARY
According to the recently published report 'Gamma Secretase - Pipeline Review, H2 2020'; Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.
Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein.
The report 'Gamma Secretase - Pipeline Review, H2 2020' outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Non Malignant Disorders, Cardiovascular and Metabolic Disorders which include indications Alzheimer's Disease, Adenoid Cystic Carcinoma (ACC), Benign Tumor, Hearing Disorders, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Soft Tissue Sarcoma, Triple-Negative Breast Cancer (TNBC), Acute Sensorineural Hearing Loss, Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Congestive Heart Failure (Heart Failure), Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Leiomyosarcoma, Leukemia, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Natural Killer Cell Lymphomas, Obesity, Solid Tumor and T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Gamma Secretase - Pipeline Review, H2 2020'; Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.
Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein.
The report 'Gamma Secretase - Pipeline Review, H2 2020' outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Non Malignant Disorders, Cardiovascular and Metabolic Disorders which include indications Alzheimer's Disease, Adenoid Cystic Carcinoma (ACC), Benign Tumor, Hearing Disorders, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Soft Tissue Sarcoma, Triple-Negative Breast Cancer (TNBC), Acute Sensorineural Hearing Loss, Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Congestive Heart Failure (Heart Failure), Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Leiomyosarcoma, Leukemia, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Natural Killer Cell Lymphomas, Obesity, Solid Tumor and T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)
- The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gamma Secretase (EC 3.4.23.) - Overview
Gamma Secretase (EC 3.4.23.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gamma Secretase (EC 3.4.23.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma Secretase (EC 3.4.23.) - Companies Involved in Therapeutics Development
Adipo Therapeutics LLC
AlzeCure Pharma AB
Astellas Pharma Inc
Audion Therapeutics BV
Ayala Pharmaceuticals Inc
Eli Lilly and Co
Everfront Biotech Inc
F. Hoffmann-La Roche Ltd
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
Pharchoice Therapeutics Inc
Pipeline Therapeutics Inc
SpringWorks Therapeutics Inc
Gamma Secretase (EC 3.4.23.) - Drug Profiles
ACD-679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACD-680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AL-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AL-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenigacestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dibenzazepine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EF-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate PSEN1 for Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSI-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-226A1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3056480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGP-555 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nirogacestat hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit PSEN1 for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PIPE-505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7185876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma Secretase (EC 3.4.23.) - Dormant Products
Gamma Secretase (EC 3.4.23.) - Discontinued Products
Gamma Secretase (EC 3.4.23.) - Product Development Milestones
Featured News & Press Releases
Sep 18, 2020: Ayala Pharmaceuticals presents positive interim data from phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma with notch activating mutations at ESMO 2020
Sep 16, 2020: SpringWorks Therapeutics announces collaboration with Children’s Oncology Group to conduct a phase 2 clinical trial of nirogacestat in pediatric patients with desmoid tumors and reports publication of nirogacestat case series in pediatric/young adult desmoid tumor patients
Sep 14, 2020: Ayala Pharmaceuticals to host virtual KOL event reviewing interim data presented at ESMO 2020 from ongoing phase 2 accuracy trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma
Jul 27, 2020: Ayala Pharmaceuticals to present updated data from ongoing phase 2 ACCURACY trial of AL101 for the treatment of R/M adenoid cystic carcinoma at the European Society for Medical Oncology (ESMO) virtual congress 2020
Jul 23, 2020: Pipeline Therapeutics initiates Phase 1/2a clinical trial of PIPE-505 in sensorineural hearing loss
Jul 22, 2020: SpringWorks Therapeutics announces full enrollment of phase 3 DeFi trial evaluating nirogacestat in adult patients with desmoid tumors
Jun 22, 2020: SpringWorks Therapeutics announces dosing of first patient in phase 1b combination study evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the treatment of Relapsed or Refractory Multiple Myeloma
Mar 18, 2020: SpringWorks Therapeutics announces issuance of new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039
Mar 03, 2020: Ayala Pharmaceuticals granted U.S. FDA Fast Track Designation for AL101 for the treatment of recurrent or metastatic adenoid cystic carcinoma
Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline’s BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH ) Annual Meeting
Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO
Sep 26, 2019: SpringWorks receives orphan status for nirogacestat in Europe
Sep 19, 2019: Ayala Pharmaceuticals announces presentation at the European Society for Medical Oncology (ESMO)
Aug 30, 2019: SpringWorks receives breakthrough status for desmoid tumour drug
May 20, 2019: Ayala Pharmaceuticals to present at ASCO Annual Meeting on investigational drug AL101 in adenoid cystic carcinoma and triple negative breast cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Gamma Secretase (EC 3.4.23.) - Overview
Gamma Secretase (EC 3.4.23.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gamma Secretase (EC 3.4.23.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma Secretase (EC 3.4.23.) - Companies Involved in Therapeutics Development
Adipo Therapeutics LLC
AlzeCure Pharma AB
Astellas Pharma Inc
Audion Therapeutics BV
Ayala Pharmaceuticals Inc
Eli Lilly and Co
Everfront Biotech Inc
F. Hoffmann-La Roche Ltd
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
Pharchoice Therapeutics Inc
Pipeline Therapeutics Inc
SpringWorks Therapeutics Inc
Gamma Secretase (EC 3.4.23.) - Drug Profiles
ACD-679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACD-680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AL-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AL-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenigacestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dibenzazepine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EF-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate PSEN1 for Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSI-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-226A1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3056480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGP-555 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nirogacestat hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit PSEN1 for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PIPE-505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7185876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma Secretase (EC 3.4.23.) - Dormant Products
Gamma Secretase (EC 3.4.23.) - Discontinued Products
Gamma Secretase (EC 3.4.23.) - Product Development Milestones
Featured News & Press Releases
Sep 18, 2020: Ayala Pharmaceuticals presents positive interim data from phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma with notch activating mutations at ESMO 2020
Sep 16, 2020: SpringWorks Therapeutics announces collaboration with Children’s Oncology Group to conduct a phase 2 clinical trial of nirogacestat in pediatric patients with desmoid tumors and reports publication of nirogacestat case series in pediatric/young adult desmoid tumor patients
Sep 14, 2020: Ayala Pharmaceuticals to host virtual KOL event reviewing interim data presented at ESMO 2020 from ongoing phase 2 accuracy trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma
Jul 27, 2020: Ayala Pharmaceuticals to present updated data from ongoing phase 2 ACCURACY trial of AL101 for the treatment of R/M adenoid cystic carcinoma at the European Society for Medical Oncology (ESMO) virtual congress 2020
Jul 23, 2020: Pipeline Therapeutics initiates Phase 1/2a clinical trial of PIPE-505 in sensorineural hearing loss
Jul 22, 2020: SpringWorks Therapeutics announces full enrollment of phase 3 DeFi trial evaluating nirogacestat in adult patients with desmoid tumors
Jun 22, 2020: SpringWorks Therapeutics announces dosing of first patient in phase 1b combination study evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the treatment of Relapsed or Refractory Multiple Myeloma
Mar 18, 2020: SpringWorks Therapeutics announces issuance of new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039
Mar 03, 2020: Ayala Pharmaceuticals granted U.S. FDA Fast Track Designation for AL101 for the treatment of recurrent or metastatic adenoid cystic carcinoma
Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline’s BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH ) Annual Meeting
Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO
Sep 26, 2019: SpringWorks receives orphan status for nirogacestat in Europe
Sep 19, 2019: Ayala Pharmaceuticals announces presentation at the European Society for Medical Oncology (ESMO)
Aug 30, 2019: SpringWorks receives breakthrough status for desmoid tumour drug
May 20, 2019: Ayala Pharmaceuticals to present at ASCO Annual Meeting on investigational drug AL101 in adenoid cystic carcinoma and triple negative breast cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Adipo Therapeutics LLC, H2 2020
Pipeline by AlzeCure Pharma AB, H2 2020
Pipeline by Astellas Pharma Inc, H2 2020
Pipeline by Audion Therapeutics BV, H2 2020
Pipeline by Ayala Pharmaceuticals Inc, H2 2020
Pipeline by Eli Lilly and Co, H2 2020
Pipeline by Everfront Biotech Inc, H2 2020
Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Pipeline by Lipopharma Therapeutics SL, H2 2020
Pipeline by Merck & Co Inc, H2 2020
Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2020
Pipeline by Pharchoice Therapeutics Inc, H2 2020
Pipeline by Pipeline Therapeutics Inc, H2 2020
Pipeline by SpringWorks Therapeutics Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Adipo Therapeutics LLC, H2 2020
Pipeline by AlzeCure Pharma AB, H2 2020
Pipeline by Astellas Pharma Inc, H2 2020
Pipeline by Audion Therapeutics BV, H2 2020
Pipeline by Ayala Pharmaceuticals Inc, H2 2020
Pipeline by Eli Lilly and Co, H2 2020
Pipeline by Everfront Biotech Inc, H2 2020
Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Pipeline by Lipopharma Therapeutics SL, H2 2020
Pipeline by Merck & Co Inc, H2 2020
Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2020
Pipeline by Pharchoice Therapeutics Inc, H2 2020
Pipeline by Pipeline Therapeutics Inc, H2 2020
Pipeline by SpringWorks Therapeutics Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
